US lags behind in providing COVID vaccine support to COVAX initiative

Credit: Brookings
Credit: Brookings

As Congress and the administration debate future funding for the global COVID-19 response, including for vaccines, we looked at how the U.S. stacks up against other donors on helping to vaccinate the world. Indeed, President Biden has convened global leaders to push for vaccination, among other COVID-19 efforts, to help achieve global vaccination coverage of 70% by September 2022, and  re-emphasized the U.S.’s global efforts in the recently released “National COVID-19 Preparedness Plan”. Here, we examine how much funding for vaccines as well as vaccine doses have been allocated. For funding, we include only financial commitments made to the COVAX Advance Market Commitment (AMC); while several donors report having committed additional funds outside of the AMC for vaccine readiness and other activities (including the U.S., Germany, and Australia), there is no centralized database available with such data from all donors. For donated doses, we include those doses pledged to COVAX, other multilateral mechanisms such as the African Vaccine Acquisition Trust (AVAT), and bilaterally (see Methods for more information).

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.
  • As of March 3, 2022, donors have provided an estimated $11.0 billion in financial assistance to the COVAX AMC for vaccination efforts and pledged to donate 2.1 billion doses to COVAX, other multilateral entities, and bilaterally (see Appendix).
  • By share of contributions, the U.S. ranks at the top, accounting for 36% of funding ($4.0 billion) and 41% of pledged doses (857.5 million) (see Figures 1 and 2).1
  • The U.S. share is greater than its share of global GDP (24%), and significantly above the next largest donor, Germany (at 11% of financial contributions and 8% of doses).
  • However, when standardized by the size of the U.S. economy (per $1 million GDP), the U.S. no longer ranks at the top, falling in rank for both financial contributions and pledged doses (see Figures 3 and 4).
    • The top financial contributor, per $1 million GDP, is Sweden, followed by Norway, Kuwait, Germany, Iceland, the U.K., Canada, Italy, Switzerland, Japan, and Saudi Arabia. The U.S. ranks 12th in financial contributions when standardized, and Sweden’s financial contribution is nearly five times that of the U.S.
    • The U.S. falls to 6th when ranked by pledged doses per $1 million GDP and is more in line, but still lower than, other large economies such as Germany and France. By this measure, Bhutan ranks first, followed by the Maldives, Germany, France, New Zealand, and then the U.S.

As Congress and the administration continue to debate whether to provide additional emergency funding for global COVID-19 efforts, this analysis may offer new insight into considerations for future U.S. support. As we show here, the U.S. is by far the largest donor in absolute measures, but much less generous when standardized by its economy.  Of course there is no perfect metric for assessing fair share in the context of a global pandemic, and none of these measures (or those used by others in the global community) is able to fully capture both the economic and non-economic benefits that would accrue to all if COVID-19 were to truly be controlled. With only 13% of those in low and middle income countries having received at least one COVID-19 vaccine dose to date, the stakes remain quite high.

screenshot amscreenshot am

Anna Rouw is a data analyst on the Global Health & HIV Policy team where she provides data analysis and policy research on a wide range of global health policy topics. Find Anna on Twitter @annarouw

Adam Wexler is an Associate Director of Global Health & HIV Policy with the Global Health team at KFF, where he focuses on analyzing the U.S. global health budget, international donor assistance for health, U.S. bilateral health agreements, and implications of foreign aid reform on U.S. global health efforts. Find Adam on Twitter @anwexler

Dr. Jen Kates is Senior Vice President and Director of Global Health & HIV Policy at KFF, where she oversees policy analysis and research focused on the U.S. government’s role in global health and on the global and domestic HIV epidemics. Find Jen on Twitter @jenkatesdc

A version of this article was originally posted at the Kaiser Family Foundation and is reposted here with permission. Kaiser Family Foundation can be found on Twitter @KFF

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
skin microbiome x final

Infographic: Could gut bacteria help us diagnose and treat diseases? This is on the horizon thanks to CRISPR gene editing

Humans are never alone. Even in a room devoid of other people, they are always in the company of billions ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.